March 2016

Hemp Bound: Dispatches from the Front Lines of the Next Agricultural Revolution

The stat sheet on hemp sounds almost too good to be true: its fibers are among the planet’s strongest, its seed oil the most nutritious, and its potential as an energy source vast and untapped. Its one downside? For nearly a century, it’s been illegal to grow industrial cannabis in the United States–even though Betsy Ross wove the nation’s first flag out of hemp fabric, Thomas Jefferson composed the Declaration of Independence on it, and colonists could pay their taxes with it. But as the prohibition on hemp’s psychoactive cousin winds down, one of humanity’s longest-utilized plants is about to be reincorporated into the American economy. Get ready for the newest billion-dollar industry.

In Hemp Bound:Dispatches from the Front Lines of the Next Agricultural Revolution, bestselling author Doug Fine embarks on a humorous yet rigorous journey to meet the men and women who are testing, researching, and pioneering hemp’s applications for the twenty-first century. From Denver, where Fine hitches a ride in a hemp-powered limo; to Asheville, North Carolina, where carbon-negative hempcrete-insulated houses are sparking a mini housing boom; to Manitoba where he raps his knuckles on the hood of a hemp tractor; and finally to the fields of east Colorado, where practical farmers are looking toward hemp to restore their agricultural economy―Fine learns how eminently possible it is for this misunderstood plant to help us end dependence on fossil fuels, heal farm soils damaged after a century of growing monocultures, and bring even more taxable revenue into the economy than its smokable relative.

Fine’s journey will not only leave you wondering why we ever stopped cultivating this miracle crop, it will fire you up to sow a field of it for yourself, for the nation’s economy, and for the planet.

Here’s What We Know About Cannabis And Cancer

This article was first published on IllegallyHealed.com.

The use of cannabis in the treatment of cancer is an emerging field in medicine. By staying up to date on the research and collaborating with other leaders in the field, physicians like my colleagues and myself can continue to meet the needs of real patients who choose not to wait for the federal government to stop obstructing human research on cannabis and cancer. Medical cannabis can be a part of an integrative plan that addresses your mind, body, spirit, family, and community.

Patients Are Reporting Relief From Cancer Symptoms And Treatment Side Effects

When used properly, cannabis can be a safe and effective treatment for nausea and vomiting caused by chemotherapy [1], chronic pain [2], and insomnia [3]. Animal studies have shown that cannabinoids can prevent the development of neuropathic pain, a common side effect of chemotherapy [4,5,6].

Via: OpenRangeStock | Shutterstock.

Via: OpenRangeStock | Shutterstock.

“Patients can often achieve significant improvements in quality of life with minimal side effects using very low doses of cannabis, in the range of 10-60mg per day (less than half a gram of herbs).”

— Dr. Dustin Sulak, Healer.com

 

Medical cannabis can help patients tolerate conventional cancer treatment, such as chemotherapy and radiation, and can be used as an adjunct to these treatments with low likelihood of drug interaction [7]. For patients with terminal cancer, cannabis offers numerous benefits in palliative care at the end of life [8].

A combination of tetrahydrocannabinol (THC), Cannabidiol (CBD), and other cannabinoids in various ratios can be used to fine-tune the benefits and minimize the psychoactive side effects of cannabis treatment.

The Use Of Cannabis To Fight Cancer And Promote Healing

In addition to the symptom relief and improvement in quality of life for cancer patients, cannabis has also demonstrated anti-cancer oncologic effects in numerous animal models [9]. A large body of anecdotal evidence suggests that human cancers also respond to treatment with cannabinoids [10,11].

Several patients have reported slowing or arresting the growth of tumors, while others have experienced full remission of aggressive cancers while using cannabis extracts [12].

To achieve these powerful anti-cancer effects, most patients require a higher dose than what is needed for symptomatic relief, often 200mg – 2,000mg cannabinoids per day, the equivalent of up to 1-2 ounces of herbal cannabis per week. While this level of treatment may be cost effective, especially if the cannabis is grown outdoors, acquiring this amount of medicine from a medical cannabis retailer could incur significant costs (see below). At these high doses, a knowledgeable medical provider must monitor the treatment to prevent side effects and interactions with conventional cancer treatment.

While any medical treatment carries certain risks, even high-dose cannabis is non-lethal and much safer than conventional chemotherapy, though the efficacy of high-dose cannabis for cancer has not been studied in humans.

If you decide to pursue a high-dose cancer treatment protocol, be prepared for the costs:

  • 1. Medical costs: Initial and follow-up visits with your oncologist, your cannabis specialist, and perhaps other complementary providers such as an acupuncturist or Reiki practitioner.
  • 2. Cannabis costs: Most adult patients will have to spend $100-$1,000 per week for a potent cannabis concentrate.
  • 3. Supplements and natural medicines: Most integrative oncologists and many cannabis specialists will recommend natural medicines that are not covered by health insurance to promote health, fight cancer, reduce side effects, and enhance the benefits of cannabis. Average cost $25-$100 per week.

Via: Wollertz | Shutterstock

Via: Wollertz | Shutterstock

“If you have cancer, and are interested in learning more about the use of cannabis, please make an appointment with a doctor or nurse practitioner that specializes in ‘cannabinoid medicine’. I am a board member of the Society of Cannabis Clinicians or contact my practice Integr8 Health in New England.”

 

I recommend reflecting on the following questions before your visit:

  • 1. What is your prognosis? How likely is success with conventional treatment?
  • 2. Are you interested in cannabis-based symptomatic treatment or a more aggressive anti-cancer approach?
  • 3. Are you willing to follow up with your oncologist to monitor the changes in your condition?
  • 4. How comfortable are you with mortality and death? Are you making fully informed medical decisions based on your personal preferences, or based on fear?

For a comprehensive review of the anticancer effects of cannabinoids, with numerous personal success stories, I suggest Justin Kander’s book, Cannabis for the Treatment of Cancer: The Anticancer Activity of Phytocannabinoids and Endocannabinoids,available online. I also welcome you to visit Healer.com to learn more about medical cannabis and how to use it therapeutically.

 

 

dr-dustin-sulakDr. Sulak is the founder of Healer.com and a renowned cannabis expert. He is the medical director of Integr8 Health which cares for over 18,000 patients and is a board member and research chair of the Society of Cannabis Clinicians. Dr. Sulak educates medical providers and patients on the clinical use of cannabis while continuing to explore the therapeutic potential of this ancient yet emerging medicine.

Sources:

1. Machado Rocha, Francisco C., et al. “Therapeutic use of Cannabis sativa on chemotherapy‐induced nausea and vomiting among cancer patients: systematic review and meta‐analysis.” European Journal of Cancer Care 17.5 (2008): 431-443.

2. Portenoy, Russell K., et al. “Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.” The Journal of Pain 13.5 (2012): 438-449.

3. Russo, Ethan B., Geoffrey W. Guy, and Philip J. Robson. “Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex®, a Cannabis‐Based Medicine.” Chemistry & Biodiversity 4.8 (2007): 1729-1743.

4. Ward, Sara Jane, et al. “Cannabidiol prevents the development of cold and mechanical allodynia in paclitaxel-treated female C57Bl6 mice.” Anesthesia and Analgesia 113.4 (2011): 947.

5. Naguib, Mohamed, et al. “Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system.” Anesthesia and Analgesia 114.5 (2012): 1104.

6. Burgos, Elisa, et al. “Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells.” European Journal of Pharmacology 682.1 (2012): 62-72.

7. Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systema0c review. Drug Metab Rev. 2014 Feb;46(1):86-95.

8. Green, Anita J., and Kay De‐Vries. “Cannabis use in palliative care–an examination of the evidence and the implications for nurses.” Journal of Clinical Nursing 19.17‐18 (2010): 2454-2462.

9. Sarfaraz, Sami, et al. “Cannabinoids for cancer treatment: progress and promise.” Cancer Research 68.2 (2008): 339-342.

10. Singh, Yadvinder, and Chamandeep Bali. “Cannabis Extract Treatment for Terminal Acute Lymphoblastic Leukemia with a Philadelphia Chromosome Mutation.” Case Reports in Oncology 6.3 (2013): 585-592.

11. Kander, J. “Cannabis for the Treatment of Cancer: The Anticancer Activity of Phytocannabinoids and Endocannabinoids” 2015.

12. Gardner, F. “Doctors stress need to document anti-cancer effects of Cannabis ‘oil’.” O’Shaughnessy’s: The Journal of Cannabis in Clinical Practice. Winter/Spring 2013.

BREAKING NEWS: US Gov’t Admits Cannabis Cures Cancer

Posted by Nurse Mary-Jane on 02/05/2016 in Medical Marijuana

Location: United States | Source: National Cancer Institute

It's time to reschedule cannabis

The moment medical marijuana has been waiting for since California first passed laws legalizing the medicinal use of cannabis, in 1996, is finally here — the US government has, at last, admitted that marijuana has medical benefit. Yes, you heard right — the US government recently updated content pages on the National Cancer Institute’s (an official division of the US Department of Health) website to include information about, cannabis and cannabinoids.

Attempting to not draw too much attention to the update, the US National Cancer Institute quietly updated their website in January, admitting that cannabis and cannabinoids kill cancer without damaging the body’s normal cells. Considering that cannabis is a Schedule 1 drug, which according to the Controlled Substances Act of 1970, means that it holds NO MEDICINAL VALUE, how could such a unbelievable admission go unnoticed by mainstream media? After all this is the plant that has been demonized as the “gateway drug”, for the past 80 years — this is BREAKING NEWS!!

The pages include a section for both patients, and physicians, and covers topics ranging from the medical effects of cannabinoids, to preclinical studies conducted using cannabis or cannabinoids. Studies in mice and rats have shown that cannabinoids may inhibit the growth of a tumor by causing cell death, blocking cell growth, and blocking the development of blood vessels need by tumors to grow. While further animal and laboratory study’s have shown evidence that cannabinoids may be able to kill cancer cells while protecting normal cells.

Additional studies have shown that there is evidence of cannabinoids protecting against inflammation and cancer of the colon; may have anti-tumor effects; may be effective in stoping breast cancer; and may make chemotherapy more effective.

Also included, is commentary about how the US government distributed cannabis to patients on a case-by-case basis under the Compassionate Use Investigational Drug (IND) program between 1978 and 1992, despite while claiming that cannabis held no medicinal value. It goes on further to say that researchers, have studied how cannabinoids act on the brain and other parts of the body, and have discovered cannabinoid receptors (molecules that bind cannabinoids) in both brain cells, and nerve cells in other parts of the body, with further evidence of cannabinoid receptors on immune system cells, suggesting that cannabinoids may play a key role in immunity, too.

It also includes information on its effectiveness to stimulate an appetite, relieve pain, reduce inflammation, control nausea and vomiting, it’s anti-anxiety effects.

Since the early 1990’s physicians have been prescribing opioid medications at an ever-increasing, and alarming rate. Resulting in an epidemic far greater in evil, than any reefer madness. The US, is now battling to counter the out-of-control, critical state of prescription drug abuse that is plaguing all classes, ethnicities, and ages. It is estimated that 52 million people have used prescription pills for non-medical reasons at least once in their lifetime, including a overwhelming large number of young people. The National Institute on Drug Abuse (NIDA) conducted a survey called “Monitoring the Future”, which found that 1 in 12 high school seniors reported non-medical use and abuse of prescription pills, while rating Vicodin, and OxyContin, as the most commonly abused drugs by adolescents. In an effort to regain control of the pill-popping monster that has been pharmaceutically created, the US is clamping down on the physicians who have writing the prescriptions, enforcing a strict new protocol that is leaving only pain management physicians with the right to prescribe pain pills.

Which leaves us to wonder only one thing – could the federal government be getting ready to reschedule cannabis, allowing for the medical research and scientific study of pot?

Firstly as a solution, to curbing the pandemic of prescription abuse among people, and patients. Secondly as a peace offering, to the pharmaceutical super-giants grotesquely over-capitalizing on the current state of the nation — cannabis will open the door to a whole new pharmaceutical industry as compensation, and while this is not something we condone, the simple fact alone is enough to have the ensure that pharmaceutical lobbyists share our agenda. Thirdly, because President Obama promised to support and sign the CARERS ACT, legalizing the medicinal use of marijuana thereby allowing for its use by the Veterans Affairs, and the vets who repeatedly keep pleading for reform — Question: Why are our vets pleading? They are our veterans, the men and women who have risked their lives, to defend and protect ours. They shouldn’t need to ask – let alone still beg or plead! As a nation, we should respectfully give them anything they need to help ease their pain and suffering, as a result of their service.
And finally – and most importantly of all – because President Obama promised change, and congressional reform of medical cannabis if the states led the way. Considering that when Obama took office in 2009 there were already 14 legal medical marijuana states, and now there’s 23 with more on the way, while 4 states and the District of Columbia have altogether legalized the recreational adult-use of pot, its clear that the states have held up their end. Now, its time for the president to uphold his.

“I don’t think rescheduling is something that I would characterize as drastic,” said U.S. Rep. Earl Blumenauer (D-Oregon), one of the key members of Congress’s cannabis reform cabal. “If we were scheduling today, marijuana would not be Schedule I — or Schedule II. In fact, it may not be scheduled at all.”

“If we were scheduling from scratch and doing so based on scientific evidence, tobacco would be Schedule I. It’s an addictive killer,” he added

In support of medicla marijuana and it’s patients, everywhere:
PLEASE SHARE THIS BREAKING NEWS with as many people in your network, as you can. Help stop reefer maddness once and for all, and spread the word that the federal government has admitted the truth, about marijuana and its medicincal value.
Help PUSH President Obama to keep his promise and reschedule cannabis, for the greater good of us all!!
Time to reschedule marijuana

mCig Inc.: High On Smoke

|

49 comments

|

About: mCig, Inc. (MCIG), Includes: VTCQ

Informer Research
Hedge fund manager, long/short equity

Summary

No assets, operating income, or business plan, yet a $25 million valuation.

Hidden shares, fake partnerships, and a history of other shenanigans.

Company facing cash squeeze.

mCig Inc. (OTCQB:MCIG) is a failed e-cigarette company surviving on a cloud of smoke. mCig started as a simple e-cig brand that audaciously described itself as a “Technology Company“; now the company calls itself a “Cannabis Product Distributor,” despite having no distribution assets. With no cash or gross profits to speak of, the company has been using its inflated stock as a currency to cover an unexplainably massive overhead: five of the six million dollars of overhead expense the company spent over the past 2.5 years was paid in shares! But with the stock price collapsing, capital has become scarce: last quarter, the company was too cash-strapped to even pay for its inventories. The company has no credible business plan, is riddled with all sorts of shenanigans, and at the current $25 million market capitalization, is set for a sober crash.

No Buzz

MCIG still sells its e-cigarette, the mCig 4.0, but nearly three years after its launch, the product is an obvious flop. In a 2013 interview, mCig’s CEO Paul Rosenberg said that “intellectual property protection for these devices is important but secondary to being a first mover and developing brand recognition.” Fast forward three years later, mCig has neither intellectual property nor brand recognition.

Among the countless pages of e-cigs on amazon.com (NASDAQ:AMZN), the mCig is nowhere to be found. Maybe they sell the product directly through their website? A simple Google search for MCIG yields a barrage of websites hocking the stock, but none selling the product; telling. Google trends says that MCIG’s homepage has too little traffic to even track! Searches for the mCig product correlate almost exactly with the stock price – now on a precipitous decline. The lack of web traffic is especially ironic given the company is now marketing itself as an expert in SEO and SEM services.

Revenue has grown, but the outrageously hyped growth (a) was off of a stupidly low base, (b) came with a big gross margin decline, and (c) is suspicious given accounting irregularities. While conveniently obfuscated by the pointless Vitacig (OTCPK:VTCQ) spinoff, a simple cleanup of mCig’s standalone financials reveals oddities including massively negative Q4 2015 gross margins (same pattern at VitacCig – see discussion below). A theory: since MCIG aggressively reserves $0 for obsolescence and warranty reserves (see MCIG 10-Q), management may have been stuffing write-offs, product returns, or warranty claims in Q4. The accounting policies haven’t changed, so this year’s revenues could also be overstated. Also worth noting, last quarter the company switched auditors – from a Salt Lake City firm to a China focused firm, which is odd.

A Thin Cloud

With the e-cigarette a flop, MCIG is now supposedly ‘focusing’ on selling $50k cannabis grow rooms, initially called mCig CannaPods but recently renamedmCigPods. The renaming is not insignificant: after noticing the change (and the fact that the mCig logo was obviously Photoshopped on the product photo) we found and called the real CannaPods company. According to a CannaPods representative, CannaPods has no affiliation with mCig,has patents pending, and their lawyers are involved with the “MCIG Situation.”

In a recent press release, mCig seems to have touched on this change, chalking it up to an inevitable progression from Pods to proprietary products. This is balderdash: the company has nothing proprietary and – as discussed further below – mCig’s only progression has been the surfacing of one bogus deal after another. Add this one to the list.

On the company website, MCIG claims to have diversified into other business lines including:

As a side note, MCIG’s supposed affiliation with CodeKush.com – a domain troller – is also ironic considering MCIG.com is currently held hostage byanother domain troller. MCIG has had to settle for the ‘.org’ site – mcig.org

  • MCIG is now supposedly in the “Finance” business. Given the fact that mCig couldn’t even afford its $50k of inventories last quarter (see $28.8k advance from related party on latest cash flows statement), this is clearly a joke. Like a 2007 mortgage broker, the company claims to be offering loans with no pesky credit checks, documents, spending restrictions, or assets required (see program description below). Shareholders should pray that this ‘business’ never becomes real!

MCIG Business Cash Flow Loan Program Description: “Banks may require lengthy applications and documentation; stipulate how the capital is to be spent; or deny applications based on FICO criteria or asset collateralization requirements. Our flexible cash flow business loan program is perfect for businesses that are looking for something more than a conventional bank loan.”mcig.org/services/financing/

  • The company claims to be involved in a poorly reviewed rolling paper company called Blanks. Nowhere on Blanks’ website, or any MCIG filing, is this relationship mentioned.
  • mCig claims to have an exclusive marketing agreement with an oil extractor called Emotek Labs; yet Emotek seems to have their own marketing person on their company Facebook page.

All of this is flimsy, bogus, and misleading to shareholders, and it doesn’t stop there. According to the mcig.org About Us page, the company has “the industry’s largest sales team,” but in the company says in their latest MCIG 10-K that “as of April 30, 2015, we had no full-time employees.” While the company may have some ‘independent contractors’, a simple LinkedIn search for mCig Inc. shows only eight people ever affiliated with the company. Most are gone and only lasted a few months.

Over the past two and a half years, the company has spent over $6 million on overhead. Where have those expenses gone? The money was clearly not invested in the business: the company has no assets and over its entire life has only spent a whopping $53k on R&D and Advertising (see latest MCIG 10-K). Despite claims to have offices in multiple states and countries, the company has just this virtual office; likely the Bronze package at $99 per month. With no IP, assets, and infrastructure to speak of, the 10-K’s list of G&A items suggests that a majority of the expenses have been blown on Paul Rosenberg’s dining and entertainment budget; i.e. shareholders are effectively funding Rosenberg’s fun and games. Don’t expect anything in return.

High on Hype

Soon after mCig became public – via a reverse merger at the end of 2013 – the stock soared to an eye-popping $400 million valuation. Since then, the stock has dropped like a lead weight, only to be intermittently propped up by bouts of outrageously hyped press releases. Examples include bogus partnership and product announcements, moonshot revenue targets, and a seemingly endless stream of illusory opportunities.

The SEC even asked Rosenberg to tone it down in this letter. Below is a scorecard analyzing ten mCig announcements over the last two years, the result of each announcement, and the stock price moves around the news. While we can only speculate about the shenanigans going on around these stock price moves, we can know for sure that – since the company pays a vast majority of its expenses in stock – Rosenberg needs that high stock price in order to keep rolling. Let the hype flow!

Links to news articles:

Vapolution Acquisition: $1.3 million in sales

Rick Ross Partnership

New Product mCig+

Vitacig Spinoff

Strategic Partnership with Force Fuels

Climagrow Partnership

1.2mm order for CBD products

7-10mm FY16 Rev Guidance

Q2 16 Revenue Guidance: 850k

Grant County, WA Grower Facility Contract

1.25 million Vaporized

On January 23, 2014 mCig ‘purchased’ Vapolution for $1.25 million; mCig’s stock soared 52% on the news. mCig’s press release claimed that the transaction “set the stage for significant synergies,” and “consolidates an industry leader with over $1.3 million in sales.” But according to this SEC inquiry, the transaction was bogus: mCig acquired none of Vapolution’s assets (then what did it include? – inquired the SEC), plus allowed Vapolution to retain 100% control of its business, the first $110k of EBITDA each year, and an ability to rescind the transaction at any time until 2019! In effect, nothing was acquired!

Vitacig: Burnt Out

Last year, mCig spun-off its Vitacig business, and as discussed above, the spin helped cloud shenanigans at both companies (see chart below for same negative gross margin in Q4 15). Perhaps fogging-out the financials was the purpose of the spin, which seems pointless otherwise. Maybe the transaction provided some strategic or operational benefit? It appears not: in the three quarters post-spin, revenues have fallen off of a cliff (along with the stock), and the company has burnt through nearly all of its cash ($130k in total); only $3k remains. Earlier this week, the CEO wrote a letter announcing yet another re-launch of the Vitacig brand; don’t hold your breath.

More Puffing

In another press release this week, management claims to have used their ‘expertise’ from “hundreds of previous cultivation projects” to get involved in constructing growing facilities that would start at $100k but supposedly grow to $550k, and then $2.4 million. What do these numbers even mean for mCig? What does mCig even bring to the table? The company has nothing proprietary, has no building experience, and – as we discussed above – has been falsely masquerading as a distributor of CannaPods’ products. The press release goes on to mention that mCig “currently [has] over $6 million in construction contracts being negotiated.” The stock is up over 80% on this nonsense.

Just to shed a little more light on this ‘transaction’: mCig’s counterparty isTravis Nyman, who has a company called Evolution Design Concepts and ownsthis 21-acre property in Mattawa, Washington, where – as the release suggests – he plans to lease parcels to growers. Cue the trumpets, chatter about multimillion-dollar figures and voila – mCig’s market capitalization is up $12 million! Back on planet earth Travis Nyman is three years behind on this property’s taxes and spent two years trying to sell the property for less than $200k; obviously unsuccessfully. It is disingenuous and misleading for Paul Rosenberg to suggest that involvement in this scheme will somehow translate to millions for the company.

Secret Stash

Speaking of sneaky business, Rosenberg converted 207 million of his shares into preferred stock that does not show up on the register. This means the stock is actually 70% more expensive than it looks on the screen! In a 2013 Seeking Alpha interview, Rosenberg said, “My preferred shares cannot be converted back to common for a year so they are not currently part of the valuation.” This is pure malarkey and shows how lowly he thinks of his shareholders’ intelligence. He was also called out by the SEC for trying to not disclose that the shares are convertible. In reality – including his preferred shares, which can be converted at any time – there are 508 million shares outstanding, so at the current stock price the market capitalization is nearly $25 million! Someone must be smoking something!

The Blunt Truth

MCIG has no assets, IP, credible team, business plan, or operating income. Management has demonstrated a clear track record of failure, bogus acquisitions, deception, manipulation, and shenanigans. The company has only $100k left in cash; yet the market cap is still $25 million. Shareholders are effectively funding Paul Rosenberg’s antics and escapades as a wannabe cannabis executive, while in the meantime he manipulates the stock price and destroys value, ultimately at shareholders’ expense. This is a zero. Steer clear before it goes up in smoke.

Disclosure: I am/we are short MCIG.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: This report was written under a pseudonym, Informer Research. The author of this report may have short positions in the company covered herein and stands to realize gains in the event that the price of the stock declines. Following publication, the author may transact in the securities of the company, and may be long, short, or neutral at any time. The author of this report has obtained all information contained herein from sources they believe to be accurate and reliable. The author of this report makes no representation, express or implied, as to the accuracy, timeliness, or completeness of any such information or with regard to the results to be obtained from its use. All expressions of opinion are subject to change without notice, and the author does not undertake to update or supplement this report or any of the information contained herein. This is not an offer to sell or a solicitation of an offer to buy any security, nor shall any security be offered or sold to any person, in any jurisdiction in which such offer would be unlawful under the securities laws of such jurisdiction.

Editor’s Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.